Keith A. Cengel

TL;DR: It is demonstrated that phosphorylation of a recombinant human immunodeficiency virus type-1 Rev protein promotes rapid formation of an efficient RNA-binding state and the described biochemical properties of the phosphorylated protein may contribute to Rev activity and possibly to HIV-1 virulence during natural infection.

TL;DR: Multimodal treatment plans combining immune checkpoint inhibitors with other therapies, including photodynamic therapy (PDT), may help to expand treatment efficacy and minimize side effects.

TL;DR: The clinical characteristics of a cohort of patients with malignant PCC/PGL are described and CVD-specific PFS is determined in order to make recommendations regarding clinical management.

TL;DR: SBRT has excellent, durable LC and CSS rates for early‐stage NSCLC, although inoperable patients had somewhat lower OS than operable patients, likely owing to greater comorbidities.

TL;DR: Higher pretreatment C TCs and persistence of CTCs posttreatment is significantly associated with increased risk of recurrence outside the targeted treatment site, which suggests that CTC analysis may potentially identify patients at higher risk for regional or distant recurrences and who may benefit from either systemic therapy and/or timely locoregional salvage treatment.